Phase IIa clinical trial on AD patientsDosage: 250 mg rilapladibPrimary endpoint: Change inAβ42 and Aβ40 level in CSFRatio of Aβ42/Aβ40 in CSFTau and p-tau in CSFWorking memory/executive function (WM/EF) composite score. The gene discussed is MAPT; the disease is Alzheimer disease.